Beactica Therapeutic’s fragment-based drug discovery platform is based on state-of-the-art SPR biosensor technology, boosted by proprietary compound collections, methodology, algorithms and experimental designs. This powerful combination enables us to determine simultaneous affinity and kinetics data, as well as novel fragment hits with well-defined interaction mechanisms and a high level of specificity – even when protein crystallisation is not possible.
Most current drugs are designed to work by interfering with the catalytic functions of the enzyme. Allosteric modulators target alternative binding sites on the enzyme, thereby providing more control over regulation and possible side effects, due to their higher specificity. Allosteric modulators introduce the possibility of fine-tuning a protein’s activity in order to achieve a much-desired variation in treatment response. They also have the potential to provide new therapy alternatives for targets that are inaccessible to active-site inhibitors and therefore undruggable.
With our unique approach, we can address a much wider range of potential targets than is achievable using structure-based methods.
Sign up for the Beactica newsletter to recieve our latest news and updates